metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	nivolumab plus SoC vs. Standard of Care (SoC)	2	0.71 [0.59; 0.86], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.68 [0.57; 0.82], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative
versus Standard of Care (SoC)
	nivolumab plus SoC vs. Standard of Care (SoC)	1	0.80 [0.68; 0.94], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.77 [0.68; 0.87], 1 RCT, I2=0% unassessable degree of certainty	-
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative
mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive